Knight Therapeutics (TSE:GUD) Trading Down 2.5% – What’s Next?

Knight Therapeutics Inc. (TSE:GUD) shares fell 2.5% during mid-day trading on Thursday . The stock traded as low as C$5.15 and last traded at C$5.15. 107,624 shares were traded during trading, an increase of 36% from the average session volume of 78,912 shares. The stock had previously closed at C$5.28.

Wall Street Analyst Weigh In

Separately, Raymond James raised shares of Knight Therapeutics to a “moderate buy” rating in a report on Friday, November 15th.

Knight Therapeutics Price Performance

The firm has a market capitalization of C$526.29 million, a P/E ratio of -26.00, a P/E/G ratio of -1,013.50 and a beta of 0.50. The stock’s 50 day simple moving average is C$5.46 and its 200 day simple moving average is C$5.65. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41.

Insider Buying and Selling at Knight Therapeutics

In related news, Director Samira Sakhia acquired 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of C$5.15 per share, for a total transaction of C$103,000.00. Also, insider Sime Armoyan sold 300,000 shares of Knight Therapeutics stock in a transaction dated Monday, September 16th. The shares were sold at an average price of C$6.13, for a total value of C$1,839,000.00. 45.62% of the stock is currently owned by corporate insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.